CT-guided radiofrequency ablation prolonged metastatic survival in patients with liver metastases from nasopharyngeal carcinoma

Figures & data

Table I.  Tumour characteristics and treatment procedures in 17 patients with liver metastases from nasopharyngeal carcinoma.

Case	Age (year)	TNM stage	Number of tumours	Maximum diameter (cm)	RF electrode	Number of ablation sites	Accumulated ablation sessions	Survival status	Metastatic Survival (months)
1	41	T1N1M0	1	3.7	RITA	1	1	dead	48.1
2	33	T2N3M0	1	9.0	RITA	3	3	dead	37.2
3	32	T4N1M1	1	2.5	cooled-tip	1	1	dead	19.8
4	72	T3N0M1	1	4.9	RITA	2	1	alive	47.3
5	72	T3N1M1	1	4.7	RITA	2	1	alive	47.3
6	72	T2N1M1	1	3.4	RITA	1	1	alive	47.3
7	29	T4N2M1	1	1.1	cooled-tip	1	1	dead	24.6
8	61	T0N3M1	1	2.8	cooled-tip	1	1	dead	113.1
9	39	T1N1M0	1	1.4	cooled-tip	1	1	alive	19.6
10	55	T2N0M0	1	4.0	RITA	1	1	dead	25.3
11	50	T3N3M1	2	3.4	RITA	1	1	alive	45.8
12	56	T2N2M1	2	2.3	cooled-tip	1	1	dead	13.8
13	44	T3N1M0	2	3.8	RITA	1	1	dead	127.3
14	49	T3N0M0	3	5.1	RITA	2	2	alive	37.5
15	38	T2N2M0	4	6.3	RITA	3	2	dead	12.5
16	46	T2N1M0	4	5.0	RITA	2	1	alive	11.8
17	43	T3N1M1	4	2.0	cooled-tip	1	1	alive	33.4

Figure 1. Metastatic survival in 17 NPC patients with LM who received RFA treatment.

Figure 2. Metastatic survival in NPC patients having 1–3 LM who did (n = 14) and did not (n = 111) receive RFA treatment.

Figure 3. Metastatic survival in 17 NPC patients with LM who received RFA treatment grouped by with or without extrahepatic metastases.